Yahoo Suche Web Suche

  1. getyourguide.de wurde im letzten Monat von mehr als 100.000 Nutzern besucht

    Für eine unvergessliche Reise – finden Sie Top-Touren und Aktivitäten an Ihrem Urlaubsort. Romeo & Julia, Arena und Wein – Verona hat viel zu bieten. Die besten Aktivitäten buchen.

Suchergebnisse

  1. Suchergebnisse:
  1. To confirm these benefits, the VERONA study, a randomized, double-blind, phase 3 study (NCT04401748) of patients with treatment-naïve HR-MDS, will assess the safety and efficacy of Ven combined with Aza including CR rate and overall survival.

    • Amer Methqal Zeidan, Jacqueline Suen Garcia, Pierre Fenaux, Uwe Platzbecker, Yasushi Miyazaki, Zhi-J...
    • 2021
  2. 2. Sept. 2022 · The ongoing phase 3 VERONA study (NCT04401748) seeks to evaluate whether the addition of venetoclax to azacitidine improves overall survival in patients with high-risk myelodysplastic syndromes. This drug combination has the potential to establish a new standard of care in this patient population.

  3. 9. Dez. 2022 · The randomized phase 2 SWOG S1117 trial compared standard-of-care azacitidine with azacitidine in combination with either lenalidomide or vorinostat in 277 patients with HR-MDS. 12 This trial showed an overall response rate (ORR) of 38% in the azacitidine group with no significant improvement in ORR in the combination groups.

  4. 12. Aug. 2020 · This confirmatory trial (VIALE-A) was designed to evaluate the efficacy and safety of the azacitidine–venetoclax combination regimen as compared with a control regimen of azacitidine and...

  5. en.wikipedia.org › wiki › Verona_trialVerona trial - Wikipedia

    The Verona Trial (Italian: processo di Verona) was a show trial held in January 1944 in the Italian Social Republic (RSI) to punish the 19 members of the Grand Council of Fascism who had voted for Benito Mussolini's removal from power in the Kingdom of Italy. Six of them had been captured by Mussolini's forces and were present for ...

  6. 26. Mai 2020 · Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona)

  7. Introduction: Azacitidine (Aza) has been shown to prolong survival in patients with treatment-naive, higher-risk myelodysplastic syndrome (HR MDS) compared to lower-intensity, conventional treatment regimens; however, improvement in clinical outcomes are needed.